{"id":"https://openalex.org/W2064059366","doi":"https://doi.org/10.1089/cbr.2005.20.300","title":"Radiotherapy of Human Xenograft NSCLC Tumors in Nude Mice with a 90 Y-Labeled Anti-Tissue Factor Antibody","display_name":"Radiotherapy of Human Xenograft NSCLC Tumors in Nude Mice with a 90 Y-Labeled Anti-Tissue Factor Antibody","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W2064059366","doi":"https://doi.org/10.1089/cbr.2005.20.300","mag":"2064059366","pmid":"https://pubmed.ncbi.nlm.nih.gov/15989475"},"language":"en","primary_location":{"id":"doi:10.1089/cbr.2005.20.300","doi":"https://doi.org/10.1089/cbr.2005.20.300","is_oa":false,"landing_page_url":"https://doi.org/10.1089/cbr.2005.20.300","pdf_url":null,"source":{"id":"https://openalex.org/S87235987","display_name":"Cancer Biotherapy and Radiopharmaceuticals","issn_l":"1084-9785","issn":["1084-9785","1557-8852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Biotherapy and Radiopharmaceuticals","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089402840","display_name":"Baiyang Wang","orcid":"https://orcid.org/0000-0002-4418-0715","observed_orcids":["https://orcid.org/0000-0002-4418-0715"]},"institutions":[{"id":"https://openalex.org/I4210124185","display_name":"Purdue Pharma (United States)","ror":"https://ror.org/030vvs717","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124185"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Baiyang Wang","raw_affiliation_strings":["BioRexis Pharmaceutical Corporation, King of Prussia, PA","Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ","BioRexis Pharmaceutical Corporation, King of Prussia, PA 19406, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioRexis Pharmaceutical Corporation, King of Prussia, PA","institution_ids":[]},{"raw_affiliation_string":"Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ","institution_ids":["https://openalex.org/I4210124185"]},{"raw_affiliation_string":"BioRexis Pharmaceutical Corporation, King of Prussia, PA 19406, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Marc Berger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124185","display_name":"Purdue Pharma (United States)","ror":"https://ror.org/030vvs717","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124185"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marc Berger","raw_affiliation_strings":["Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ","institution_ids":["https://openalex.org/I4210124185"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028655389","display_name":"Gregg R. Masters","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124185","display_name":"Purdue Pharma (United States)","ror":"https://ror.org/030vvs717","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124185"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregg Masters","raw_affiliation_strings":["Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ","institution_ids":["https://openalex.org/I4210124185"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068678429","display_name":"Earl F. Albone","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124185","display_name":"Purdue Pharma (United States)","ror":"https://ror.org/030vvs717","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124185"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Earl Albone","raw_affiliation_strings":["Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ","institution_ids":["https://openalex.org/I4210124185"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016935464","display_name":"Qifeng Yang","orcid":"https://orcid.org/0000-0003-0576-8513","observed_orcids":["https://orcid.org/0000-0003-0576-8513"]},"institutions":[{"id":"https://openalex.org/I4210124185","display_name":"Purdue Pharma (United States)","ror":"https://ror.org/030vvs717","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124185"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qifeng Yang","raw_affiliation_strings":["Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ","institution_ids":["https://openalex.org/I4210124185"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063193141","display_name":"Josephine Sheedy","orcid":"https://orcid.org/0000-0001-9615-2727","observed_orcids":["https://orcid.org/0000-0001-9615-2727"]},"institutions":[{"id":"https://openalex.org/I4210124185","display_name":"Purdue Pharma (United States)","ror":"https://ror.org/030vvs717","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124185"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Josephine Sheedy","raw_affiliation_strings":["Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ","institution_ids":["https://openalex.org/I4210124185"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083347722","display_name":"Yolanda M. Kirksey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124185","display_name":"Purdue Pharma (United States)","ror":"https://ror.org/030vvs717","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124185"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yolanda Kirksey","raw_affiliation_strings":["Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ","institution_ids":["https://openalex.org/I4210124185"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067141363","display_name":"Lisa G. Grimm","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124185","display_name":"Purdue Pharma (United States)","ror":"https://ror.org/030vvs717","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124185"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa Grimm","raw_affiliation_strings":["Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ","institution_ids":["https://openalex.org/I4210124185"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100408154","display_name":"Bo Wang","orcid":"https://orcid.org/0000-0002-9196-6366","observed_orcids":["https://orcid.org/0000-0002-9196-6366"]},"institutions":[{"id":"https://openalex.org/I4210124185","display_name":"Purdue Pharma (United States)","ror":"https://ror.org/030vvs717","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124185"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bo Wang","raw_affiliation_strings":["BioRexis Pharmaceutical Corporation, King of Prussia, PA","Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioRexis Pharmaceutical Corporation, King of Prussia, PA","institution_ids":[]},{"raw_affiliation_string":"Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ","institution_ids":["https://openalex.org/I4210124185"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Judith Singleton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124185","display_name":"Purdue Pharma (United States)","ror":"https://ror.org/030vvs717","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124185"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Judith Singleton","raw_affiliation_strings":["Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ","institution_ids":["https://openalex.org/I4210124185"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109989704","display_name":"Daniel A. Soltis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124185","display_name":"Purdue Pharma (United States)","ror":"https://ror.org/030vvs717","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124185"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Soltis","raw_affiliation_strings":["Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Purdue Pharma L.P., Department of Immunotherapeutics, Cranbury, NJ","institution_ids":["https://openalex.org/I4210124185"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210124185"],"apc_list":null,"apc_paid":null,"fwci":0.4858,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.68133064,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"20","issue":"3","first_page":"300","last_page":"309"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10358","display_name":"Advanced Radiotherapy Techniques","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3108","display_name":"Radiation"},"field":{"id":"https://openalex.org/fields/31","display_name":"Physics and Astronomy"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tissue-factor","display_name":"tissue factor","score":0.8709999918937683},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9819999933242798},{"id":"https://openalex.org/keywords/radioimmunotherapy","display_name":"radioimmunotherapy","score":0.7110000252723694},{"id":"https://openalex.org/keywords/yttrium-90","display_name":"yttrium-90","score":0.8700000047683716},{"id":"https://openalex.org/keywords/anti-tissue-factor-antibody","display_name":"anti-tissue factor antibody","score":0.871999979019165},{"id":"https://openalex.org/keywords/xenograft-tumor-model","display_name":"xenograft tumor model","score":0.7089999914169312},{"id":"https://openalex.org/keywords/tumor-targeting","display_name":"tumor targeting","score":0.527999997138977},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.7599999904632568},{"id":"https://openalex.org/keywords/tumor-regression","display_name":"tumor regression","score":0.4699999988079071},{"id":"https://openalex.org/keywords/immunodeficient-mice","display_name":"immunodeficient mice","score":0.6110000014305115},{"id":"https://openalex.org/keywords/tumor-overexpression","display_name":"tumor overexpression","score":0.42500001192092896}],"concepts":[{"id":"https://openalex.org/C204232928","wikidata":"https://www.wikidata.org/wiki/Q899285","display_name":"Immunohistochemistry","level":2,"score":0.6988130211830139},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.6486204862594604},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5951759815216064},{"id":"https://openalex.org/C186738567","wikidata":"https://www.wikidata.org/wiki/Q412841","display_name":"Tissue factor","level":3,"score":0.5628479719161987},{"id":"https://openalex.org/C2776146153","wikidata":"https://www.wikidata.org/wiki/Q7281276","display_name":"Radioimmunotherapy","level":4,"score":0.47025004029273987},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.46369659900665283},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.45375844836235046},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.41401752829551697},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.4114013612270355},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.38598158955574036},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.35041964054107666},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2846871018409729},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.24276146292686462},{"id":"https://openalex.org/C2778382381","wikidata":"https://www.wikidata.org/wiki/Q179217","display_name":"Coagulation","level":2,"score":0.1800689399242401},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.15756449103355408}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000906","descriptor_name":"Antibodies","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000941","descriptor_name":"Antigens","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000532","qualifier_name":"radiotherapy","is_major_topic":true},{"descriptor_ui":"D004705","descriptor_name":"Endocytosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011829","descriptor_name":"Radiation Dosage","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013925","descriptor_name":"Thromboplastin","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D014018","descriptor_name":"Tissue Distribution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015021","descriptor_name":"Yttrium Radioisotopes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015021","descriptor_name":"Yttrium Radioisotopes","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D015021","descriptor_name":"Yttrium Radioisotopes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1089/cbr.2005.20.300","doi":"https://doi.org/10.1089/cbr.2005.20.300","is_oa":false,"landing_page_url":"https://doi.org/10.1089/cbr.2005.20.300","pdf_url":null,"source":{"id":"https://openalex.org/S87235987","display_name":"Cancer Biotherapy and Radiopharmaceuticals","issn_l":"1084-9785","issn":["1084-9785","1557-8852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Biotherapy and Radiopharmaceuticals","raw_type":"journal-article"},{"id":"pmid:15989475","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15989475","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer biotherapy & radiopharmaceuticals","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W178032782","https://openalex.org/W1512026049","https://openalex.org/W1551609808","https://openalex.org/W1843766617","https://openalex.org/W1854111724","https://openalex.org/W1967013447","https://openalex.org/W1971214445","https://openalex.org/W1971365462","https://openalex.org/W1981289456","https://openalex.org/W1983999973","https://openalex.org/W1984352482","https://openalex.org/W1993166478","https://openalex.org/W1993459732","https://openalex.org/W1994805429","https://openalex.org/W1995387334","https://openalex.org/W2034656907","https://openalex.org/W2035715457","https://openalex.org/W2042247727","https://openalex.org/W2049262861","https://openalex.org/W2065151015","https://openalex.org/W2066763853","https://openalex.org/W2073841672","https://openalex.org/W2075829745","https://openalex.org/W2082255225","https://openalex.org/W2091969556","https://openalex.org/W2101137688","https://openalex.org/W2129901781","https://openalex.org/W2132872213","https://openalex.org/W2142863599","https://openalex.org/W2409279657"],"related_works":["https://openalex.org/W2324633269","https://openalex.org/W2565688096","https://openalex.org/W7096888266","https://openalex.org/W1983999973","https://openalex.org/W2602919227","https://openalex.org/W2027052735","https://openalex.org/W1984864918","https://openalex.org/W2043461574","https://openalex.org/W2059573069","https://openalex.org/W2043672753"],"abstract_inverted_index":{"Tissue":[0],"factor":[1],"(TF)":[2],"is":[3,29,86],"a":[4,20,70,104,158,168],"type":[5],"I":[6],"transmembrane":[7],"protein":[8],"and":[9,26,38,57,85,130,162],"the":[10,13,36,81,126,136,152],"initiator":[11],"of":[12,41,61,83,108,113,116,138,154],"extrinsic":[14],"blood":[15],"coagulation":[16],"pathway.":[17],"TF":[18,42,79],"plays":[19],"critical":[21],"role":[22],"in":[23,31,44,97,140,146],"tumor":[24,95,101,144],"development":[25],"its":[27,132],"overexpression":[28],"observed":[30],"many":[32],"tumors.":[33],"To":[34],"understand":[35],"prevalence":[37],"relative":[39],"level":[40],"expression":[43],"non-small-cell":[45],"lung":[46],"cancer":[47],"(NSCLC),":[48],"we":[49,124],"analyzed":[50],"50":[51,159],"NSCLC":[52,63],"tumors":[53,64,139,156,166],"by":[54],"immunohistochemical":[55],"staining":[56],"found":[58],"that":[59],"88%":[60],"human":[62],"overexpressed":[65],"TF.":[66],"We":[67],"then":[68],"generated":[69],"high":[71],"affinity":[72],"anti-TF":[73],"antibody,":[74],"TF278,":[75],"which":[76],"specifically":[77],"binds":[78],"on":[80],"surface":[82],"cells":[84],"internalized":[87],"upon":[88],"binding.":[89],"An":[90],"111In-labeled":[91],"TF278":[92],"demonstrated":[93],"favorable":[94],"accumulation":[96],"an":[98,141],"SW-900":[99,142,155,165],"xenograft":[100,143],"model":[102,145],"with":[103,128,172],"maximum":[105],"mean":[106],"percent":[107],"injected":[109],"dose":[110,161,171],"per":[111],"gram":[112],"tissue":[114],"(%ID/g)":[115],"73.1%":[117],"at":[118,157,167],"96":[119],"hours":[120],"postinjection.":[121],"In":[122],"addition,":[123],"labeled":[125],"antibody":[127],"90Y":[129],"tested":[131],"ability":[133],"to":[134],"inhibit":[135],"growth":[137,153],"immunocompromised":[147],"mice.":[148],"The":[149],"90Y-TF278":[150],"slowed":[151],"microCi":[160,170],"completely":[163],"regressed":[164],"150":[169],"little":[173],"toxicity.":[174]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}